Cargando…
MDM2/X Inhibitors as Radiosensitizers for Glioblastoma Targeted Therapy
Inhibition of the MDM2/X-p53 interaction is recognized as a potential anti-cancer strategy, including the treatment of glioblastoma (GB). In response to cellular stressors, such as DNA damage, the tumor suppression protein p53 is activated and responds by mediating cellular damage through DNA repair...
Autores principales: | Miles, Xanthene, Vandevoorde, Charlot, Hunter, Alistair, Bolcaen, Julie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8296304/ https://www.ncbi.nlm.nih.gov/pubmed/34307171 http://dx.doi.org/10.3389/fonc.2021.703442 |
Ejemplares similares
-
Radiosensitization Effect of Gold Nanoparticles in Proton Therapy
por: Cunningham, Charnay, et al.
Publicado: (2021) -
Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma
por: Bolcaen, Julie, et al.
Publicado: (2021) -
Recombinant Endostatin as a Potential Radiosensitizer in the Treatment of Non-Small Cell Lung Cancer
por: Cunningham, Charnay, et al.
Publicado: (2023) -
Perspective on the Use of DNA Repair Inhibitors as a Tool for Imaging and Radionuclide Therapy of Glioblastoma
por: Everix, Liesbeth, et al.
Publicado: (2022) -
A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma
por: Bolcaen, Julie, et al.
Publicado: (2021)